Selecting the right treatment for inflammatory skin disease is a costly trial-and-error process that is becoming increasingly problematic. Dermcyt changes this by using proprietary detergents to noninvasively sample skin and apply machine learning to protein-level biomarkers, enabling personalized treatment selection based on each patient’s unique biology. Blavatnik funding will accelerate our path to market by allowing us to: 1) finalize predictive modeling, 2) manufacture clinical-grade collection kits, and 3) establish and validate our proteomic assay in a CLIA/CAP-certified lab. These milestones will position Dermcyt to launch its first clinical testing platform and revolutionize how inflammatory skin diseases are treated.